Gustave Roussy Joins the Worldwide Innovative Network (WIN) in Personalized Cancer Medicine
Posted: Thursday, April 29, 2021
Gustave Roussy and Worldwide Innovative Network (WIN) in personalised cancer medicine consortium join forces to advance innovative cancer research
VILLEJUIF, FRANCE, April 29, 2021
EINPresswire.com
About Gustave Roussy
Gustave Roussy, Europe's leading cancer centre, is a global cancer centre of expertise in the fight against cancer entirely dedicated to patients. It treats all cancers at every stage of life and offers its patients individualised care combining innovation and a humane approach.
Twenty-six percent of its new patients are included in clinical trials. It brings together on two sites (Villejuif and Chevilly Larue) 3,100 professionals whose missions are care, research and teaching.
Contact
https://www.gustaveroussy.fr/en
Press contact:
Claire Parisel | +33 1 42 11 50 59 claire.parisel@gustaveroussy.fr
About WIN Consortium
WIN Consortium is a non-profit association headquartered in France. The WIN network assembles 35 world-class academic medical centres, industries (pharmaceutical and diagnostic companies), research organisations and patient advocates spanning 19 countries and 4 continents, aligned to launch trials using its genomics and transcriptomics biomarker platform to
bolster Precision Oncology across the world.
WIN is the organiser of the WIN symposia in Precision Oncology.
WIN Contact:
Vladimir Lazar, MD, PhD
Worldwide Innovative Network WIN Consortium
+33 6 61 09 15 22
This press release can be viewed online at: https://www.einpresswire.com/article/539675904
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world.
Please see our Editorial Guidelines for more information.
© 1995-2021 IPD Group, Inc. All Rights Reserved.